Results 21 to 30 of about 36,016 (212)

DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)

Viruses, 2022
Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference and is administrable on a ...
Carmen Hidalgo-Tenorio, Juan Pasquau, David Vinuesa, Sergio Ferra, Alberto Terrón, Isabel SanJoaquín, Antoni Payeras, Onofre Juan Martínez, Miguel Ángel López-Ruz, Mohamed Omar, Javier de la Torre-Lima, Ana López-Lirola, Jesús Palomares, José Ramón Blanco, Marta Montero, Coral García-Vallecillos   +15 more
doaj   +1 more source

Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals:the relative roles of drift and selection [PDF]

, 2000
Human immunodeficiency virus type 1 (HIV-1) rapidly develops resistance to lamivudine during monotherapy, typically resulting in the appearance at position 184 in reverse transcriptase (RT) of isoleucine instead of the wild-type methionine (M184I) early ...
Frost, SDW, Boucher, CAB, Leigh Brown, AJ, Nijhuis, M, Schuurman, R   +4 more
core   +1 more source

Suppression of HBV by Tenofovir in HBV/HIV coinfected patients : a systematic review and meta-analysis [PDF]

, 2013
Background: Hepatitis B coinfection is common in HIV-positive individuals and as antiretroviral therapy has made death due to AIDS less common, hepatitis has become increasingly important. Several drugs are available to treat hepatitis B. The most potent
Thomas Reiberger, Richard Gilson, Noriyoshi Kuzushita, Firouze Bani-Sadr (432319), Nüesch, R, David Dunn (37023), Marina Núñez, Lionel Tan, Stephan Christoph, Peters, M, Tan, L (Lionel), Pillay, Deenan, Huw Price, de Vries-Sluijs, T, Reto Nüesch, Dunn, David, Peters, Marion, Kuzushita, N, Kuzushita Noriyoshi, Firouze Bani-Sadr, Bani-Sadr, Firouze, Mauss Stefan, Reiberger, Thomas, Stefan Mauss, Gilson, Richard, Mauß, Stefan, Mamta K Jain, Theodora de Vries-Sluijs, Tan, Lionel, Gilson, R, Price, H, Gilson Richard, Huw Price (300124), Jain Mamta K., Peters Marion, Reiberger Thomas, Thomas Reiberger (143056), Nüesch Reto, Price, Huw, Richard Gilson (125405), David Dunn, Reto Nüesch (432324), Nüesch, Reto, Marina Núñez (432323), Pillay Deenan, Deenan Pillay (7888), Price Huw, Tan, L, Tan Lionel, Dunn David, Kuzushita, Noriyoshi, Christoph Stephan (283267), Stephan, C, Christoph Stephan, Pillay, D, Núñez Marina, Núñez, M, Stefan Mauss (143062), Bani-Sadr, F, Peters, M (Marjolein), Jain, MK, Bani-Sadr Firouze, de Vries-Sluijs Theodora, Stephan, Christoph, Theodora de Vries-Sluijs (432320), Lionel Tan (124548), Dunn, D, Marion Peters, Reiberger, T, Mamta K. Jain, Noriyoshi Kuzushita (432322), Mamta K. Jain (432321), Marion Peters (403490), Mauss, S, Jain, Mamta K., Núñez, Marina, Deenan Pillay, Nueesch, R, Vries-Sluijs, Theodora de   +78 more
core   +1 more source

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. [PDF]

, 2012
BACKGROUND: The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy.
Phillips, AN, Alec Miners, Valentina Cambiano (146513), von Wyl Viktor, Phillips, Andrew N, Andrew N Phillips, Bertagnolio, S, Cambiano, V, Jens Lundgren, Valentina Cambiano, Silvia Bertagnolio, Pillay Deenan, Pillay, Deenan, Deenan Pillay (7888), Bertagnolio, Silvia, Miners Alec, Jordan, MR, Michael R. Jordan (146520), Cambiano, Valentina, von Wyl, Viktor, Viktor von Wyl, Phillips Andrew N., Jordan, Michael R, Cambiano Valentina, Miners, Alec, Pillay, D, Bertagnolio Silvia, Lundgren Jens, Miners, A, Andrew N. Phillips (146556), Lundgren, Jens, Alec Miners (146534), Viktor von Wyl (146506), Silvia Bertagnolio (57174), Michael R Jordan, Deenan Pillay, von Wyl, V, Lundgren, J, Jens Lundgren (146550), Jordan Michael R.   +39 more
core   +1 more source

Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety. [PDF]

, 2008
Lamivudine has been demonstrated safe and efficacious in the short term in a large cohort of children with chronic hepatitis B (CHB), but optimal duration of treatment has not been elucidated and limited data on the safety of long-term lamivudine ...
International Pediatric Lamivudine Investigator Group, Jonas, M, Little, N, Ferreira, G, Gardner, S   +4 more
core   +1 more source

Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study

, 2021
Background: In the ART-PRO pilot trial there were no virological failures through 48 weeks of treatment with dolutegravir plus lamivudine in suppressed individuals with and without archived lamivudine resistance-associated mutations (RAMs) detected ...
Delgado Vázquez, Rafael, Pulido Ortega, Federico, Arribas JR, Rial Crestelo, David, Rubio García, Rafael   +4 more
core   +1 more source

Baseline Data on Viral Suppression, Treatment Adherence and Mental Health in Peripartum Girls and Young Women With HIV in Zimbabwe. [PDF]

J Int AIDS Soc
ABSTRACT Introduction Peripartum adolescent girls and young women (AGYW) with HIV have lower viral suppression compared to older women. But the recently introduced dolutegravir‐based regimens and psychosocial peer motivation may improve viral control.
Chawana-Mutingwende TD, Ngara B, Mudadi LS, Tauya TT, Sibanda M, Mutambanengwe-Jacob M, Andifasi P, Malunda B, Chidemo T, Mapfunde A, Nyakudya S, Mufumisi AZ, Chirenda TH, Chitambo T, Nderecha WTS, Murandu C, Gwande M, Muringayi K, Micah Bongo R, Okochi H, Kuncze K, Mushavi A, Willis N, Webb K, Gandhi M, Stranix-Chibanda L.   +25 more
europepmc   +2 more sources

Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children [PDF]

, 2007
: Objective: To describe the long-term efficacy over 5 years of regimens including combinations of abacavir, lamivudine and/or zidovudine in previously untreated children in the PENTA 5 trial. Design: PENTA 5 was a 48-week randomised controlled trial
COMPAGNUCCI A, LEVY J, FEITERNA SPERLING C, BUTLER K, WALKER AS, WINTERGERST U, GIBB DM, GIAQUINTO, CARLO, SAIDI Y, DE ROSSI, ANITA, HARPER L, CANDEIAS E, CASTELLI GATTINARA G, PILLAY D, DELLA NEGRA M, Paediatric European Network for the Treatment of AIDS, GREEN H   +16 more
core   +2 more sources

Clinical trial of lamivudine in children with chronic hepatitis B. [PDF]

, 2002
BACKGROUND: Lamivudine therapy is effective for chronic hepatitis B infection in adults. We evaluated the efficacy and tolerability of lamivudine as a treatment for chronic infection with hepatitis B virus (HBV) in children.
Schwarz, KB, Jonas, M.M., Kelley, Deirdre A, Bell, M Steve, Greensmith, M.J., Bell, MS, Schwarz, K.B., Kelly, Deirdre, Schwarz, Kathleen B, Aerias, JA, International Pediatric Lamivudine Investigator Group., Gardener, SD, Greensmith, MJ, Bell, M.S., Mierski, J, Sokal, E.M., Badia, Isabel B, Greensmith, Martin J, Little, N.R., Little, Nancy R, Little, NR, Jonas, MM, Jonas, Maureen M, Mizerski, Jacek, Gardner, Stephen D, Sokal, EM, Badia, IB, Areias, Jorge A, Badia, I.B., Sokal, Etienne, Gardner, S.D., Areias, J.A., Mizerski, J.   +32 more
core   +1 more source

Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting

HIV Research & Clinical Practice, 2022
Objectives: To evaluate the impact of a treatment switch to dolutegravir plus lamivudine on the soluble inflammatory biomarkers of HIV-infected patients treated in a real-life setting.
Francesca Lombardi, Simone Belmonti, Davide Moschese, Massimiliano Fabbiani, Alberto Borghetti, Arturo Ciccullo, Elena Visconti, Simona Di Giambenedetto   +7 more
doaj   +1 more source